Navigation Links
Angiotech Pharmaceuticals, Inc. announces financial results for the first quarter ended March 31, 2009
Date:4/30/2009

VANCOUVER, April 30 /PRNewswire-FirstCall/ - Angiotech Pharmaceuticals, Inc. (NASDAQ: ANPI, TSX: ANP) today announced its financial results for the first quarter ended March 31, 2009.

"We were pleased to post solid results for our first quarter in what has been a difficult business environment for many companies," said Dr. William Hunter, President and CEO of Angiotech. "Sales in our proprietary Surgical and Interventional business areas continued to show very promising growth, with Quill SRS in particular garnering greater acceptance in new hospitals and surgical disciplines, and we continued to realize expense reductions as compared to the prior quarter. Additionally, our royalty revenue increased as compared to the fourth quarter of last year, indicating an improved market position for our partner Boston Scientific and higher sales of paclitaxel-eluting stents."

    First Quarter Financial Highlights

    -  Total revenue was $88.3 million. Total revenue was $63.2 million on
       an adjusted basis, excluding one-time license revenue of $25 million
       received from our partner Baxter International Inc. ("Baxter")
       relating to our amended and restated Distribution and License
       Agreement, as announced on March 31, 2009.

    -  Net product sales were $46.1 million.

    -  Royalty revenue was $17.1 million.

    -  Adjusted EBITDA (earnings before interest, taxes, depreciation and
       amortization, adjusted to exclude certain non-cash and non-recurring
       items) was $14.6 million.

    -  Research and development expenses were $6.1 million, and as adjusted
       to exclude non-cash stock-based compensation expenses and
       non-recurring termination related costs were $5.7 million. These
       results compare to $7.7 million and $6.9 million, respectively, in
       the fourth quarter of 
'/>"/>
SOURCE Angiotech Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21

Related biology technology :

1. Angiotech announces date of annual general meeting of shareholders
2. Angiotech Pharmaceuticals, Inc. Announces Conference Call And Webcast
3. Angiotech Pharmaceuticals, Inc. announces License Agreement with Baxter International Inc.
4. Angiotech announces positive results from Bio-Seal(TM) clinical study
5. Angiotech Pharmaceuticals, Inc. announces financial results for the fourth quarter ended December 31, 2008
6. Angiotech Pharmaceuticals, Inc. announces new Senior Secured Term Loan and Credit Facilities
7. Angiotech Pharmaceuticals announces time change of conference call and webcast
8. Angiotech announces termination of note purchase agreement with Ares Management and New Leaf Venture Partners
9. Angiotech Announces Webcast and Call-in Numbers for Annual and Special General Meeting of Shareholders
10. Angiotech Announces Extension of the Expiration Date of its Tender Offer for Senior Floating Rate Notes Due 2013 and 7.75% Senior Subordinated Notes Due 2014
11. Angiotech receives CE Mark approval of HemoStream(TM) Chronic Dialysis Catheter
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... Texas , Dec. 24, 2014  Vermillion, ... focused on gynecologic disease, announced today that the ... investors including Oracle Investment Management, Jack W. ... directors. Total proceeds were $10.5 million, before offering ... capital and general corporate purposes. Under ...
(Date:12/24/2014)... 2014 “Preparative & Process Chromatography ... Consumables (Columns, Solvents, Buffers, Valves, Guages, Seals), Accessories, ... - Forecasts to 2019” provides a detailed overview ... market trends, and strategies impacting the preparative and ... forecasts of the revenue and share analysis. ...
(Date:12/24/2014)... Boston, MA (PRWEB) December 23, 2014 ... presentation, Dr. James L. Sherley, director of the Adult ... attention on an often overlooked and under appreciated unique ... “Asymmetric Self-Renewal by Distributed Stem Cells: Misunderstood in the ... his message to congress participants. He gave the ...
(Date:12/24/2014)... 2014 On Friday, December 19, ... the Omnibus and Continuing Resolution Appropriations Act of ... a condition eligible to receive funding through the ... the Department of Defense (DoD). The Hydrocephalus Association ... Capitol Hill, is celebrating this victory for the ...
Breaking Biology Technology:Vermillion Announces Closing of Equity Financing 2Vermillion Announces Closing of Equity Financing 3Preparative and Process Chromatography Market is expected to reach $9 billion by 2019 - New Report by Marketsandmarkets 2Preparative and Process Chromatography Market is expected to reach $9 billion by 2019 - New Report by Marketsandmarkets 3Preparative and Process Chromatography Market is expected to reach $9 billion by 2019 - New Report by Marketsandmarkets 4Adult Stem Cell Technology Center, LLC’s Director Sherley's Address on What’s Holding Back Regenerative Medicine Featured on Omics Group Website 2Adult Stem Cell Technology Center, LLC’s Director Sherley's Address on What’s Holding Back Regenerative Medicine Featured on Omics Group Website 3Adult Stem Cell Technology Center, LLC’s Director Sherley's Address on What’s Holding Back Regenerative Medicine Featured on Omics Group Website 4Rare Brain Condition Now Eligible for Department of Defense Research Dollars 2
... samples in 1-day shift, INDIANAPOLIS, Sept. 14 ... for HIV provides shorter turnaround,time and less hands-on ... to,a new study published in Clinical Chemistry and ... Medical Laboratory Bremen, concludes that,Roche,s new HIV-1 test ...
... PTN ) announced today results for its fourth,quarter and ... loss of,$6.1 million, or ($0.07) per basic and diluted share, ... loss of $7.9 million, or ($0.11) per basic,and diluted share, ... ended June 30, 2007 were $2.6 million, compared to $5.0 ...
... Sept. 13 Reed Group Ltd., publisher,of The ... leader in,return- to-work and disability management products and ... (ACC) has,purchased an enterprise license of the MDA. ... use of the MDA throughout various government agencies,and ...
Cached Biology Technology:Roche Real-Time HIV Test is Faster and Less Labor-Intensive Than Competitor's 2Palatin Technologies, Inc. Reports Fourth Quarter and Fiscal Year End 2007 Results; Teleconference and Webcast to be held on September 18, 2007 2Palatin Technologies, Inc. Reports Fourth Quarter and Fiscal Year End 2007 Results; Teleconference and Webcast to be held on September 18, 2007 3Palatin Technologies, Inc. Reports Fourth Quarter and Fiscal Year End 2007 Results; Teleconference and Webcast to be held on September 18, 2007 4Palatin Technologies, Inc. Reports Fourth Quarter and Fiscal Year End 2007 Results; Teleconference and Webcast to be held on September 18, 2007 5Palatin Technologies, Inc. Reports Fourth Quarter and Fiscal Year End 2007 Results; Teleconference and Webcast to be held on September 18, 2007 6Palatin Technologies, Inc. Reports Fourth Quarter and Fiscal Year End 2007 Results; Teleconference and Webcast to be held on September 18, 2007 7Palatin Technologies, Inc. Reports Fourth Quarter and Fiscal Year End 2007 Results; Teleconference and Webcast to be held on September 18, 2007 8Reed Group Ltd. Announces Enterprise License for New Zealand's Accident Compensation Corporation 2
(Date:12/22/2014)... , Dec. 22, 2014  The 2014 ... the biometrics industry as Acuity Market Intelligence reports ... may finally be open. Acuity forecasts that intensifying ... devices that incorporate biometrics will drive a global ... billion biometric devices by 2020.   ...
(Date:12/19/2014)... --  LaunchKey , the first decentralized mobile authentication and ... Things era, today announced the close of $3 million ... by Metamorphic Ventures with participation from ENIAC Ventures, Crosslink ... LaunchKey has raised $4 million to date, and will ... bring LaunchKey to market in 2015. LaunchKey ...
(Date:12/17/2014)... -- Valencell, a leader in performance biometric data sensor ... leaders such as Intel, Jabra, Atlas, and Scosche to ... These products will be showcased at CES 2015, taking ... . "Our partners choose PerformTek biometrics, ... with the clinical data to back it up," said ...
Breaking Biology News(10 mins):First Season of Holiday Shopping with Mobile Biometric Payments Wraps Up With a Present for Biometrics Industry: A Rosy Forecast for More Than 2 Billion Users of 4.8 Billion Mobile Biometric Devices by 2020 2LaunchKey Raises $3 Million in Additional Funding Led by Metamorphic Ventures 2LaunchKey Raises $3 Million in Additional Funding Led by Metamorphic Ventures 3Valencell PerformTek Biometrics Power the Most Accurate Wearables at CES 2015 2
... similar elasticity to bone could mean a new generation of ... results from more rigid implant materials, such as titanium. Researchers ... which is even lighter than solid aluminum and can be ... and aluminum. In a new paper, researchers have reported ...
... groundbreaking research of Dr. Doris Taylor was achieved recently ... license agreement with Miromatrix Medical Inc. Dr. Taylor,s ... announced that it had created a beating animal heart ... holds the promise of one day enabling the replacement ...
... CINCINNATI -- Scientists have discovered a molecular pathway that works ... may lead to new therapies for repairing injury in a ... week,s Proceedings of the National Academy of Sciences ... Children,s Hospital Medical Center and the Brigham & Women,s Hospital ...
Cached Biology News:New material mimics bone to create better biomedical implants 2U of Minnesota finalizes license agreement to form start-up company based on Doris Taylor research 2Scientists discover molecular pathway for organ tissue regeneration and repair 2
... nmol (individual) with sequence siTrio siRNA ... to your target gene of interestis our most ... more than 75% knockdown of your target gene ... for transfection and confirmation of optimal transfection with ...
The Bio-Plex Manager version 3.0 to 4.0 workstation software upgrade kit is used to upgrade existing Bio-Plex Manager version 3.0 software to version 4.0 security edition software....
... rigid macroporous hydrophilic media. The rigid polymer ... pressures, while the macroporous beads enhance access ... reduces nonspecific binding. Macro-Prep High Q support ... very high flow rates and resolution. It ...
... --- a cocktail of 3 siRNAs specifically ... our most popular product. The siTrio reagent ... of your target gene when used under ... and confirmation of optimal transfection with one ...
Biology Products: